Jean MOSSER Group

Translational OncoGenomics (TOnG)

Jean MOSSER

Group leader

> Email: jean.mosser@univ-rennes1.fr

> Phone: + 33 2 99 28 42 71 / + 33 2 23 23 44 91

 

Our translational project is within the scope of the improvement of solid tumors personalized medicine by using and identifying new relevant epigenetic and genetic biomarkers. The use of these molecular markers will improve the tumor molecular stratification with an impact on molecular diagnosis, therapeutic response prediction, patient monitoring and clinical trial enrollment.

Read more >

Major publications

Selected Publications

  • From the Core to beyond the Margin: a genomic picture of glioblastoma intratumor heterogeneity.
    Aubry M*, de Tayrac M*, Etcheverry A, Clavreul A, Menei P, Mosser J.
    OncoTarget. 2015 May.

    DGKI Methylation Status Modulates the Prognostic Value of MGMT in Glioblastoma Patients Treated with Combined Radio-Chemotherapy with Temozolomide.
    Etcheverry A*, Aubry M*, Idbaih A, Vauleon E, Marie Y, Menei P, Boniface R, Figarella-Branger D, Karayan-Tapon L, Quillien V, Sanson M, de Tayrac M, Delattre JY, Mosser J.
    PloS One. 2014 Sep.

    Human Glioblastoma Stem-Like Cells are More Sensitive to Allogeneic NK and T Cell-Mediated Killing Compared with Serum-Cultured Glioblastoma Cells
    Avril T, Vauleon E, Hamlat A, Saikali S, Etcheverry A, Delmas C, Diabira S, Mosser J, Quillien V.
    Brain Path. 2012 Mar.

    A 4-gene signature associated with clinical outcome in high-grade gliomas.
    de Tayrac M*, Aubry M*, Saïkali S, Etcheverry A, Surbled C, Guénot F, Galibert MD, Hamlat A, Lesimple T, Quillien V, Menei P, Mosser J.
    Clin Cancer Res. 2011 Jan.

    DNA methylation in glioblastoma: impact on gene expression and clinical outcome.
    Etcheverry A, Aubry M, de Tayrac M, Vauléon E, Boniface R, Guénot F, Saikali S, Hamlat A, Menei P, Quillien V, Mosser J.
    BMC Genomics. 2010 Dec.

Subscribe to our newsletter